Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.

Indian J Med Res · 2023 · PMC10284354 · PMID 37040228

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

However, survival data seen in patients with metastatic PDAC receiving mFOLFIRINOX in this study appear comparable to outcomes seen with full dose FOLFIRINOX in the seminal Phase III trial, implying that this dose modification may not be significant.

also in 1,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.